Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK ...

The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, today announced the successful completion of its first-in-human (FIH) feasibility study of its disease-modifying ...

The Dr Trust Bestest Compressor Nebulizer is a highly efficient and reliable device for home use. It features a powerful ...

The medication segment was the largest in 2022, favored for its cost-effectiveness and common use as a first-line treatment. .Centriacinar Emphysema Growth: The centriacinar segment, primarily linked ...

Background Hypoxic pulmonary vasoconstriction leads to an increase in pulmonary artery pressure (PAP) and potentially right ...

For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations. Today we ...